CION Ameerpet
Chemotherapy has finished, the scans have improved, and now the conversation has turned to a treatment you carry on with while you are well. If you have been searching maintenance therapy ovarian cancer since that appointment, this page sets out which options exist, which test results decide between them, and what a delay in recurrence honestly buys you.
Maintenance therapy is treatment you continue after chemotherapy has already worked. The scans are clear or nearly clear, the CA-125 has settled, and you feel better than you have in months. Nothing visible is being treated. What is being treated is the tendency of ovarian cancer to come back — and it is treated at the point when the amount of disease left in the body is at its smallest.
That distinction changes what the treatment is for and how it feels. Chemotherapy is intensive, given in cycles, and aimed at disease you can see. Maintenance is lower-intensity, taken over months, and aimed at disease you cannot. Most women on maintenance are working, travelling and running their households, which is the point: the treatment is only worth having if the life it protects is one you can still lead.
There is no single maintenance treatment. There are three routes — PARP-inhibitor-class tablets, anti-angiogenic infusions, and hormonal treatment in slower-growing subtypes — and which is right for you depends on your tumour subtype, what you received alongside chemotherapy, and your BRCA and HRD test results. A page that tells you maintenance is simply a good idea has skipped the only part of the decision that is actually yours.
Maintenance is started once chemotherapy has produced a complete or partial response. If disease is still growing, that is a different conversation and a different treatment.
The benefit of every maintenance option is recorded as time before the cancer is seen to grow again — and that time varies enormously between the three routes and between test results.
For some women the honest expected gain is large. For others it is modest enough that observation is a legitimate choice. Your test results decide which of those conversations you are having.
In the PRIMA trial, women with newly diagnosed advanced ovarian cancer at high risk of recurrence, who were in response after platinum-based chemotherapy, were randomly assigned to PARP-inhibitor-class maintenance or to placebo — regardless of BRCA status. Median progression-free survival was 13.8 months with maintenance against 8.2 months with placebo across the whole trial population, and 21.9 against 10.4 months in the women whose tumours tested HRD-positive. That result is why maintenance is now discussed with almost every woman finishing first-line chemotherapy for advanced disease — and why HRD testing, rather than guesswork, decides how much benefit to expect. Source: González-Martín A et al., New England Journal of Medicine (2019); NCCN Ovarian Cancer guidelines.
Read down the left column until you find your own situation. Maintenance decisions feel confusing because women in adjacent rows are offered quite different treatment, for reasons that are rarely spelled out at the time.
| Your situation after first-line treatment | Maintenance usually discussed | What it is aiming at |
|---|---|---|
| Advanced high-grade serous or endometrioid cancer with a germline or tumour BRCA1 or BRCA2 mutation, in complete or partial response to platinum-based chemotherapy | PARP-inhibitor-class maintenance, taken daily at home for a planned period of about two years | The largest recorded delay before recurrence of any maintenance option in ovarian cancer — years rather than months in the trial populations. |
| Advanced disease, BRCA-negative but HRD-positive on tumour testing | PARP-inhibitor-class maintenance, in some plans combined with anti-angiogenic therapy | A clear delay, smaller than in BRCA-mutated disease but large enough to be worth the months of treatment for most women. |
| Advanced disease that is BRCA-negative and HRD-negative (homologous-recombination-proficient) | PARP-inhibitor-class maintenance is an option under some guidelines; anti-angiogenic maintenance is often preferred | A modest delay. This is the row where an honest conversation about whether the gain justifies the treatment matters most. |
| Stage 4 disease, or disease left behind at surgery — a high risk of early progression | Anti-angiogenic therapy given alongside chemotherapy and then continued as maintenance | Delaying progression in the group the trials showed gains most from this class. |
| Low-grade serous cancer, or a hormone-receptor-positive tumour | Hormonal maintenance treatment, usually a daily tablet | Long-term control of a slower-growing cancer that responds poorly to chemotherapy in the first place. |
| A platinum-sensitive recurrence, in response after further platinum-based chemotherapy | PARP-inhibitor-class maintenance, where it has not already been given | Extending the treatment-free interval before the next line of chemotherapy is needed. |
| Early-stage disease completely removed at surgery, with no residual disease | Usually no maintenance — structured surveillance instead | Avoiding months of treatment and its side effects where the risk of recurrence is already low. |
*This table describes how these decisions are usually framed, not a prescription for your case. Germline BRCA, tumour BRCA and HRD results should all be available before the maintenance decision is made — if they were not sent at diagnosis, that is worth asking about rather than assuming the window has closed. Detail on each route: PARP-inhibitor maintenance and anti-angiogenic therapy.
Maintenance is taken at home, often for a year or more, which is exactly why it needs a low threshold for picking up the phone. Most of these are handled with a dose reduction or a short planned break rather than by stopping treatment altogether.
Treat this as urgent. Blood counts can fall on maintenance, and an infection with a low neutrophil count needs assessment the same day.
Anaemia is the commonest reason maintenance doses are adjusted. It builds gradually, so it is easily put down to recovery from chemotherapy when a blood count would settle the question.
A falling platelet count. Report it before your next scheduled review rather than waiting for it.
Specific to anti-angiogenic therapy, which is why both are checked before every dose. Both are usually manageable, and both need acting on rather than watching.
Uncommon, but it needs the same day. Bowel obstruction and perforation are the serious risks of the anti-angiogenic class, particularly after bowel surgery.
Maintenance delays recurrence; it does not remove the possibility of it. Symptoms you recognise from before deserve a scan, not reassurance over the phone.
Do not stop maintenance on your own because of side effects. Dose reduction keeps most women on treatment, and treatment continued at a lower dose does more for you than treatment that is abandoned. Call your team first and let them make the change.
Bring your histopathology report, your BRCA or HRD result, your chemotherapy summary and your end-of-treatment scan. In 45 minutes a medical oncologist can tell you which maintenance route the evidence supports in your situation, and how much it is likely to be worth.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Where your test results mean the expected gain would be small, we will say so plainly instead of starting treatment by default.
The practical questions arrive after the decision has been made, and they are rarely covered in the appointment where maintenance is first suggested.
Maintenance usually begins a few weeks after the last chemotherapy cycle, once blood counts have recovered and the end-of-treatment scan and CA-125 have confirmed the response. The early weeks are when nausea, fatigue and falling blood counts are most likely, and when most dose adjustments are made.
This is worth knowing in advance, because women who expect the first months to be the worst tend to get through them. Side effects that appear early often settle as the body adjusts or as the dose is refined, and a difficult first six weeks does not predict a difficult year.
Expect a full blood count and a clinical review every month, more frequently at the start. On an anti-angiogenic route, blood pressure and urine protein are checked before each infusion. Liver and kidney function are checked periodically.
Scans are done at agreed intervals rather than constantly, with CA-125 followed alongside them. Scanning more often does not improve outcomes, and it reliably increases the anxiety of the days before each result — a real cost that deserves weighing rather than dismissing.
Fatigue, nausea and anaemia are the common problems on the tablet routes; raised blood pressure, protein in the urine and slower wound healing on the anti-angiogenic route. Almost all of these are managed by reducing the dose or pausing briefly, and most women continue treatment afterwards.
Tell your team early rather than enduring it until the next review. A dose reduction made in week six keeps a woman on treatment for the full course; the same problem left unreported for three months often ends it.
Most women on maintenance work, travel and manage their households. The tablet routes need no hospital visit for the treatment itself, only for monitoring, which is why being close to a centre that can do your blood counts matters more than being close to the hospital where you had chemotherapy.
Plan travel around the monitoring rather than around the treatment. If any procedure is being considered, including dental work, say that you are on maintenance — the anti-angiogenic class affects wound healing and needs a planned gap before and after surgery.
Maintenance runs for months to years, so the question is not what one month costs but what the whole course costs and what your cover pays for. Insurance approval, scheme eligibility and patient-assistance programmes all take time to arrange, and they are far easier to sort out before treatment starts than midway through it.
Ask for the expected duration, the monitoring schedule and the total cost in writing at the point of the decision. A plan that has to stop early for financial reasons is worse than a plan chosen realistically at the outset. At CION cost is discussed at the first consultation rather than after treatment has begun.
First-line maintenance is usually planned for a fixed period rather than continued indefinitely. Finishing it unsettles many women, because the treatment that felt like protection stops and surveillance takes over. That reaction is common and worth naming with your team rather than carrying alone.
Follow-up continues with clinical review, CA-125 and imaging where indicated. If the disease does return, having had maintenance does not close off later options — it changes which ones are considered and in what order. See ovarian cancer recurrence for how the platinum-free interval shapes that decision.
Nearly every number quoted for maintenance therapy is a progression-free survival figure: the time before the cancer is seen to grow again. It is a genuine benefit and not a statistical trick. Months or years without recurrence are months or years without chemotherapy, without admissions, and without the particular dread of waiting on a scan result. Ask any woman who has had a long remission what that time was worth.
It is not, however, the same measurement as living longer overall. Overall survival takes many more years of follow-up to establish and is muddied by every treatment given after a trial ends. For some maintenance routes in some groups an overall survival benefit has been shown; for others it has not, and the honest answer is that the delay itself is the benefit. A doctor who blurs the two is not helping you decide.
The second honest point is that these figures describe groups. A median progression-free survival of 21.9 months does not mean your recurrence is scheduled for month 22 — half the women in that group did better, some by a long way, and half did worse. The same caution applies to the stage-specific ovarian survival percentages you will find online, most of which were compiled before biomarker-directed maintenance existed, average across substages and subtypes that behave very differently, and mix women who had complete surgical cytoreduction with women who did not. For context, 81.0% of CION ovarian cancer patients are alive at one year, against a national figure of 73.7% — again a group figure, not a forecast for you.
The most tangible gain. A longer remission means a longer interval before the next line of chemotherapy, and that interval itself influences how well the next line is likely to work.
Maintenance lowers the chance of the cancer growing during the period it is given. It does not remove the possibility of recurrence, and symptoms that return still need investigating.
Every published number is an average across a trial population. Stage, subtype, surgical outcome and your BRCA or HRD status matter far more to your own outlook than any headline median.
*One-year survival rates. CION figures reflect CION’s treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups, not individuals — discuss your own prognosis with your treating oncologist.
Two questions bring most women to a second opinion at this point. The first is whether months of treatment are worth it when they already feel well. The second, usually asked more quietly, is whether the recommendation reflects their own test results or is simply what everybody is given now. Both are fair, and both need longer than a five-minute review slot.
Your first consultation at CION is free and runs to about 45 minutes. Bring the histopathology report, the germline BRCA result and any tumour BRCA or HRD report, the chemotherapy summary, and the end-of-treatment scan and CA-125. Much of the useful work is unglamorous: reading your own results with you, identifying which row of the table above you genuinely fall into, and being specific about the expected gain. Every case is discussed at a tumour board rather than decided by a single doctor.
The division of care should be clear before you decide. Chemotherapy and maintenance therapy are delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh, alongside genetic counselling, BRCA and HRD testing, nutrition support, survivorship care and long-term follow-up. Debulking and other gynaecologic-oncology surgery, HIPEC and PET-CT are coordinated with specialist partner centres, where they are performed and may be billed. We say that upfront rather than leaving it to be discovered when an invoice arrives. More on ovarian cancer treatment at CION.
Free and unhurried. Long enough to read your BRCA and HRD reports with you and say plainly how much benefit the evidence supports in your case.
Genetic counselling, germline BRCA testing and HRD testing are arranged through CION — and ordered at diagnosis, when the results can still change the plan.
Monthly blood counts and reviews at whichever of our 35+ centres is closest to you, rather than repeat trips into one city hospital for a tablet you take at home.
Expected duration, monitoring schedule and total cost, set out at the decision rather than after it. Decisions for healing, not billing.
Maintenance therapy is treatment continued after chemotherapy has already worked, given while you are in remission rather than to shrink disease that is still visible. Ovarian cancer usually responds well to platinum-based chemotherapy but has a strong tendency to return, most often in the first two to three years. Maintenance targets that tendency at the point when the amount of disease left in the body is smallest. There are three routes: PARP-inhibitor-class tablets taken daily at home, anti-angiogenic therapy given as an infusion every few weeks, and hormonal treatment in low-grade serous disease. Which one is discussed with you depends on your tumour subtype, what you received alongside chemotherapy, and your BRCA and HRD test results.
Maintenance is discussed with almost every woman who has finished first-line chemotherapy for advanced epithelial ovarian cancer and is in complete or partial response. It is generally not offered where early-stage disease has been completely removed at surgery and the risk of recurrence is already low, because months of treatment and its side effects would buy very little. Between those two ends, the decision turns on test results. A BRCA mutation predicts the largest gain from PARP-inhibitor-class maintenance; an HRD-positive result without a BRCA mutation predicts a clear but smaller one; an HRD-negative result predicts a modest one, and that is the situation where the choice genuinely deserves discussion rather than a default.
It is planned for a fixed period rather than continued indefinitely. First-line PARP-inhibitor-class maintenance is typically planned for about two years, sometimes longer where treatment is well tolerated and the disease has not returned. Anti-angiogenic maintenance runs for a set number of cycles after chemotherapy, over roughly a year in most plans. Hormonal maintenance in low-grade serous disease often continues for longer, because that subtype behaves more like a chronic condition. Treatment may finish earlier if side effects cannot be managed with a dose reduction, or if the disease returns. Ask for the intended duration at the start, because it affects both what you plan around and what the full course will cost.
For some routes in some groups, yes; for others the demonstrated benefit is a longer remission rather than longer overall survival. Almost every headline figure quoted for maintenance is progression-free survival, meaning the time before the cancer is seen to grow again. That is a real benefit: time without chemotherapy, without admissions, and without waiting on the next scan. Overall survival is a different measurement that needs many more years of follow-up and is confounded by every treatment given afterwards. When a number is quoted to you, ask which of the two it describes. Both kinds of figure describe groups rather than individuals, and neither predicts what will happen to you specifically.
No, and generally no. Maintenance is not chemotherapy. The tablet routes are taken at home rather than infused in a day-care unit, and hair loss is not a typical effect of them. Anti-angiogenic therapy is given by infusion but is also not chemotherapy and does not usually cause hair loss either. What maintenance does share with chemotherapy is the need for monitoring: monthly blood counts on the tablet routes, and blood pressure and urine protein checks before each anti-angiogenic infusion. The common problems are fatigue, nausea and anaemia on the tablets, and raised blood pressure and protein in the urine on the infusions. Most are managed with a dose reduction rather than by stopping treatment.
Maintenance is stopped and the situation is reassessed with imaging and CA-125. Recurrence during maintenance is not a failure of your treatment or of you, and it does not mean nothing further can be done. What matters most for the next decision is the platinum-free interval, meaning how long it has been since platinum-based chemotherapy finished. A longer interval usually means platinum-based treatment can be used again, often with a good response. A short interval points towards a different class of treatment instead. Your team will also review whether surgery has any role at recurrence, which is coordinated with specialist partner centres rather than performed at CION.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology for ovarian cancer in-house, which covers chemotherapy and maintenance therapy across more than 35 centres in Telangana and Andhra Pradesh, together with genetic counselling and BRCA and HRD testing, nutrition support and long-term follow-up. Monitoring blood counts and reviews can be done at whichever centre is closest to you rather than requiring repeat trips into one city hospital. Debulking and other gynaecologic-oncology surgery, HIPEC and PET-CT are coordinated with specialist partner centres, where they are performed and may be billed, and we state that upfront. Every maintenance decision is discussed at a tumour board.